Form 4: Actuate Therapeutics Insider Transactions: Bios Equity Partners Converts Preferred Stock and Notes Following IPO

Following Actuate Therapeutics' IPO, Bios Equity Partners and related entities converted preferred stock and convertible notes into common stock and exercised warrants, resulting in adjustments to their beneficial ownership.

Summary

• This Form 4 filing details changes in beneficial ownership of Actuate Therapeutics, Inc. (ACTU) stock by Leslie W. Kreis, related entities including Cavu Advisors, LLC, Cavu Management, LP, and various Bios Equity Partners funds.
• The transactions occurred on August 14, 2024, following Actuate Therapeutics' initial public offering (IPO).
• The transactions primarily involve the conversion of convertible notes and preferred stock (Series A, B-1, B-2, B-3, B-4, and C) into common stock.
• Warrants to purchase common stock were also exercised on a cashless basis, with the issuer withholding shares to cover the exercise price.
• Leslie W. Kreis is a director and reported as a 10% owner.
• The filing is one of six related to the same event, split due to SEC EDGAR system limitations on the number of reporting persons and rows per form.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing detailing insider transactions following an IPO. It doesn't inherently convey positive or negative sentiment, but rather provides factual information. The sentiment is neutral to slightly positive as it reflects the completion of the IPO process.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions, allowing investors to monitor the actions of company insiders and large shareholders.

Stakeholder Impact

• The conversions and warrant exercises impact the ownership structure of the company, potentially affecting the influence of major shareholders.
• The increased number of common shares outstanding may have a dilutive effect on existing shareholders.

Key Dates